E. Grischke

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.

A. Schneeweiss, F. Marmé, D. Strumberg, 2019, Breast.

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.

O. Gluz, S. Kuemmel, R. Kates, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

M. Lux, P. Fasching, A. Schneeweiss, 2018, Journal of bone oncology.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

N. Harbeck, O. Gluz, S. Kuemmel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

K. Friedrichs, N. Harbeck, O. Gluz, 2019, Breast Cancer Research and Treatment.